IND-enabling preclinical development of a sustained-release pritelivir intravaginal ring for the treatment and prophylaxis of genital herpes in women
Active Project Grant Awarded Last action
- Award ID
- R44AI136201
- Recipient
-
Auritec Pharmaceuticals, LLC UEI QX8KP6JKQ2L8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,910,561
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 91% complete
- Originally
- Place of performance
- Pasadena, CA 91107, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $1,000,000 | |
| Amendment | $1,025,000 | |
| Amendment | $1,025,000 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,000,000 | |
| Original award | $860,561 |
Quick answers
Who received award R44AI136201?
R44AI136201 was awarded to Auritec Pharmaceuticals, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on February 1, 2018.
How much is award R44AI136201 worth?
$4,910,561 has been obligated on R44AI136201.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award